Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Issue Date
2010-07MeSH
Antineoplastic AgentsDrug Resistance, Neoplasm
Female
Fusion Proteins, bcr-abl
Humans
Incidental Findings
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Middle Aged
Piperazines
Protein Kinase Inhibitors
Pyrimidines
RNA, Messenger
RNA, Neoplasm
Remission Induction
Tumor Markers, Biological
Metadata
Show full item recordCitation
Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia. 2010, 34 (7):e176-7 Leuk. Res.Journal
Leukemia researchDOI
10.1016/j.leukres.2010.01.025PubMed ID
20153526Item Type
ArticleLanguage
enISSN
1873-5835ae974a485f413a2113503eed53cd6c53
10.1016/j.leukres.2010.01.025
Scopus Count
Collections
Related articles
- BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
- Authors: Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T
- Issue date: 2007 Dec 1
- Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.
- Authors: Barbany G, Höglund M, Simonsson B, Swedish CML Group
- Issue date: 2002 Aug 15
- Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
- Authors: Carella AM
- Issue date: 2007 Mar
- Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
- Authors: Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW
- Issue date: 2010 Apr 10
- Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
- Authors: Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A
- Issue date: 2005 Apr 15